Maria E. Bedoya Toro - 17 Aug 2021 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
Senior Vice President
Signature
/s/ Gerald T. Proehl, Attorney-in-Fact
Issuer symbol
DRMA
Transactions as of
17 Aug 2021
Net transactions value
$0
Form type
4
Filing time
17 Aug 2021, 12:51:09 UTC
Previous filing
12 Aug 2021
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRMA Common Stock Conversion of derivative security +9,162 +47% 28,674 17 Aug 2021 By Munera Family Trust F1, F7
transaction DRMA Common Stock Conversion of derivative security +19,512 +68% 48,186 17 Aug 2021 By Munera Family Trust F2, F7
transaction DRMA Common Stock Conversion of derivative security +4,878 +10% 53,064 17 Aug 2021 By Munera Family Trust F3, F7
transaction DRMA Common Stock Conversion of derivative security +17,421 +33% 70,485 17 Aug 2021 By Munera Family Trust F4, F7
transaction DRMA Common Stock Conversion of derivative security +13,658 +19% 84,143 17 Aug 2021 By Munera Family Trust F5, F7
holding DRMA Common Stock 30,487 17 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRMA Series 1d Preferred Stock Conversion of derivative security $0 -61,821 -100% $0.000000* 0 17 Aug 2021 Common Stock 9,162 By Munera Family Trust F1, F7
transaction DRMA Series 1a Preferred Stock Conversion of derivative security $0 -400,000 -100% $0.000000* 0 17 Aug 2021 Common Stock 19,512 By Munera Family Trust F2, F7
transaction DRMA Series 1b Preferred Stock Conversion of derivative security $0 -100,000 -100% $0.000000* 0 17 Aug 2021 Common Stock 4,878 By Munera Family Trust F3, F7
transaction DRMA Series 1c Preferred Stock Conversion of derivative security $0 -357,142 -100% $0.000000* 0 17 Aug 2021 Common Stock 17,421 By Munera Family Trust F4, F7
transaction DRMA Series 1 Preferred Stock Conversion of derivative security $0 -280,000 -100% $0.000000* 0 17 Aug 2021 Common Stock 13,658 By Munera Family Trust F5, F7
transaction DRMA Series 1a Warrants Conversion of derivative security $0 -100,000 -100% $0.000000* 0 17 Aug 2021 Common Stock 4,878 By Munera Family Trust F6, F7
transaction DRMA Warrant to Purchase Common Stock Conversion of derivative security $0 +4,878 $0.000000 4,878 17 Aug 2021 Common Stock 4,878 $20.50 By Munera Family Trust F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
F2 The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
F3 The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
F4 The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
F5 The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
F6 The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.
F7 Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.